Serina Therapeutics shares are trading higher after the company announced the completion of sentinel dosing in Cohort 1 of its ongoing Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease. Also, a Form 4 filing showed its Director purchased 1,000 shares at an average price of $2.03 each.